Compare Sibanye Stillwater Ltd (SBSW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs 10X Genomics Inc — how do they compare? Sibanye Stillwater Ltd trades at $13.04 (market cap $9.35B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Sibanye Stillwater Ltd and 10X Genomics Inc are close in size by market cap, and Sibanye Stillwater Ltd pays a 6.27% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SBSW | TXG | |
|---|---|---|
Market Cap | $9.35B | $8.55B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $67.29 |
52-Week Low | $8.00 | $11.34 |
Enterprise Value | $10.29B | $8.08B |
Dividend Yield | 6.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $12.90, up 0.86% with a bullish technical signal. The company shows strong operational momentum with 54% YoY revenue growth and 111% EBITDA growth in H1 2026. Valuation metrics appear attractive with P/E of 10.2 and P/S of 0.88. Analyst consensus is mixed with 43% buy ratings and $14.00 price target, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential upside from current levels supported by strong H1 2026 results and disciplined capital allocation. Key risks include commodity price volatility and the company's recent history of net losses. The stock presents a turnaround opportunity with improving cash flow trends and operational efficiency gains.
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
